200 results about "Glutamic-Pyruvic Transaminase" patented technology

The invention discloses hepatic fibrosis detection system, relating to the technical field of hepatic fibrosis research. The hepatic fibrosis detection system comprises a transient elastography device an input device, a classifier and an output device, wherein the input device is used for receiving ages and serum biochemical indicators, and the serum biochemical indicators at least comprise blood platelet, hyaluronic acid (HA), serum direct bilirubin (DBIL), prothrombin time (PT), alanine aminotransferase/serum glutamic pyruvic transaminase (ALT; GPT), and aspartate transaminase/serum glutamic oxalacetic transaminase (AST; GOT); the classifier is used for performing hepatic fibrosis staging according to the ages and the serum biochemical indicators and received by the input device and transient elasticity imaging data; and the output device is used for outputting of hepatic fibrosis staging results of the classifier. The hepatic fibrosis detection system of the embodiment disclosed by the invention has the advantages of noninvasiveness, strong practicability, simple and convenient method, low price, good safety and the like.

The invention discloses a traditional Chinese medicine capsule for treating fatty liver and alcoholic liver. The traditional Chinese medicine capsule is characterized by comprising the following substances in parts by weight of 60-68 parts of hawthorn, 40-46 parts of semen cassia, 18-24 parts of dried tangerine or orange peel, 20-24 parts of rhizoma pinellinae praepa, 30-34 parts of tuckahoe, 40-47 parts of rhizoma alismatis, 40-47 parts of root of red-rooted salvia, 20-26 parts of rheum officinale, 40-44 parts of oriental wormwood, 60-70 parts of astragalus mongholicus, 29-33 parts of polygonum multiflorum, 18-23 parts of honewort, and 19-24 parts of honey-fried licorice root. The traditional Chinese medicine capsule disclosed by the invention is free of toxic and side effects, and has significant curative effects in the aspects of treatment of fatty liver, restoring of liver iconography, improving of the liver function, reducing of serum glutamic pyruvic transaminase and serum total bilirubin, and reducing of blood triglyceride.

The invention provides application of geniposide in preparation of a medicine for treating fatty liver disease, and relates to novel application of the geniposide. The geniposide can be used for preparing the medicine for treating fatty liver disease. The medicine can be prepared into commonly used clinical preparation according to conventional method, and the oral solid preparation is better, such as granule, tablet and capsule. The medicine contains 50 to 100mg/kg of geniposide by weight. The medicine is subjected to the test on high fat diet-induced golden hamster with fatty liver disease; and as the test shown, the medicine can obviously reduce the contents of serum TG (Triacylglycerol) and the content of liver tissue TG, and inhibit the raise of the activity of serum ALT (Glutamic-Pyruvic Transaminase) and AST (Glutamic Oxalacetic Transaminase), and has the effect of treating the fatty liver disease, so that the geniposide can be used for preparing the medicine for treating the fatty liver disease.

The invention relates to a method for producing a microbial feed by utilizing flammulina velutipes residues through segmental cultivation and joint transformation and fermentation of funguses and bacteria. The method comprises the following process steps: raw material processing, fungus leavening agent formulation, compound bacteria leavening agent manufacturing, segmental solid fermentation, drying, crushing and the like. The microbial feed produced by adopting the method is free of any chemical additive ingredient, has a natural fermentation flavor, contains various amino acids, vitamins and other nutrient substances, as well as a great amount of biological active enzymes, and can remarkably reduce the contents of glutamic pyruvic transaminase, glutamic oxalacetic transaminase, cholesterol, triglyceride and urea nitrogen in blood and improve the quality of animal livers and kidneys, thereby being a super-quality and competitive-price green biological feed for feeding livestock.

An oil/fat composition comprising 5 to 99.9 wt. % of a monoglyccride having, as fatty acid constituents thereof, 15 to 90 wt % of an ω 3-unsaturated fatty acid having less than 20 carbon atoms, 1 to 80 wt. % of an ω 9-unsaturated fatty acid and 2 to 50 wt. % of an ω 9-unsaturated fatty acid; and 0.1 to 49.9 wt. % of a diglyceride, wherein a weight ratio of the diglyceride to the monoglyceride is less than 1 and the content of a polyunsaturated fatty acid having at least 4 carbon-to-carbon double bonds is 20% or less in all the fatty acid constituents. The oil/fat composition according to the present invention has excellent processing properties, good taste and excellent lowering action against glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) levels in blood. It is useful not only for pharmaceuticals but also for preventive or remedial foods of feeds effective for hepatic function disturbances or obesity.

The invention discloses a blood lipid-reducing health-care product, which is prepared by mixing the following components in percentage by weight: 50 to 60 percent of natto flour, 25 to 35 percent of fiveleaf gynostemma herb, 1.5 to 2.5 percent of lentinan, 3 to 6 percent of puerarin, and 8 to 15 percent of tea polyphenol. The blood lipid-reducing health-care product can regulate blood lipid, clean blood vessels, reduce blood viscosity, improve and relieve vascular fibrosis, protect liver functions, reinforce cardiocerebral activities, reduce triglyceride, cholesterol and glutamic-pyruvic transaminase, promote density lipoprotein, restore carrier protein defects, delay aging and the like.

The invention provides application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Mannuronic acid oligomers with different molecular weights, which are obtained by degrading polymannuronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance and glutathione level of the serum, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.

The invention discloses an application of a ferroptosis inhibitor in preparation of a medicine for treating an acute liver injury. A ferroptosis inhibitor is pretreated to remarkably reduce levels ofglutamic-pyruvic transaminase ALT and glutamic oxalacetic transaminase AST in serum after the acute liver injury induced by sodium thiosulfate TAA; an MDA content in liver tissues after the TAA-induced acute liver injury is reduced, and the contents of reduced glutathione GSH and glutathione peroxidase GSH-PX in the liver tissues are increased; infiltration of inflammatory cells in the TAA-inducedacute liver injury to a liver is reduced; and a protective effect of the ferroptosis inhibitor on the TAA-induced acute liver injury is related to inhibition of hepatocyte ferroptosis, and ferroptosis marker gene glutamic acid/cystine reverse transporter xCT and Gpx4 glutathione peroxidase 4 in a TAA-induced acute liver injury model can be remarkably improved by the ferroptosis inhibitor.

The invention discloses a dry chemical bigeminal reagent strip for simultaneously detecting glutamic oxalacetic transaminase and glutamic-pyruvic transaminase. The dry chemical bigeminal reagent strip is characterized in that two sections of test paper pads are contained, and each test paper pad is composed of four layers of films which are the diffusion film on the surface layer, the rapid glass fiber filter film on the second layer, the mixed fiber film on the third layer and the reaction film on the bottom layer. Corresponding reactants are adsorbed on the reaction films, and when a detected object is added into a sample inlet hole, the detected object is uniformly dispersed on the two test paper pads through the surface diffusion films and then reaches the reaction films on the bottom layer to carry out reacting. Meanwhile, a lower supporting layer of the reagent strip is provided with two test holes which are connected with the reaction films on the bottom layer respectively, in the reacting process, dihydrocoenzyme I (NADH) adsorbed on the reaction films is oxidized into NAD+, the descend range of the absorbance at 340 nm is tested, and therefore the content of the corresponding tested object is obtained. The reagent strip can be used for rapidly determining the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase in the human whole blood or serum or plasma, and therefore clinical monitoring and adjuvant therapies of liver diseases are promoted.

The invention discloses a production method for microbial fermentation complete feed by combining multi-strain joint transformations. The method for producing a microbial feed by utilizing needle mushroom residues, and performing mould and bacteria staged cultivation, and joint transformations and fermentation comprises the following process steps of processing raw materials, compounding a mould fermentation agent, preparing a composite bacterial fermentation agent, performing staged solid fermentation, drying, crushing and the like. The microbial feed prepared by the production method disclosed by the invention has natural fermentation fragrance without any chemical additive component and contains nutrient substances of various amino acids, vitamins and the like and a large number of bioactive enzymes, so that content of glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, cholesterol, triglyceride and urea nitrogen in blood can be greatly reduced, the liver quality and the kidney quality of animals are improved, and the microbial fermentation complete feed is an environment-friendly biological feed with good quality and low price for feeding domestic animals.

Purpose of the invention is to provide a reagent bar capable of half quantitative/ quantitative detecting whether content of glutamic-pyruvic transaminase (GPT) inside human body is normal or not rapidly, and relevant fabricating method. The reagent bar includes PVC hard strip for supporting reaction. The hard strip possesses carrier film of adsorbing L-alanine, pyruvate oxidase, and alpha-ketoglutarate. Belonging to fast test in micro scale, the disclosed product is one-off consumption material for testing. Range for detecting GPT is 0-1000U/L.

The invention discloses lactobacillus rhamnosus CCFM1060, a fermented food and a preparation method of a bacterial agent; increase of the abundance of Proteus induced by high lipid and high cholesterol diet is significantly reduced, and the occurrence of diseases such as urinary tract blockage, intestinal bacterial migration and enteritis is reduced; the lipid metabolism disorder of NAFLD patientsis significantly improved; insulin resistance of NAFLD mice is significantly improved; increase of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase in serum can be re-adjusted; theconcentration of low-density lipoprotein cholesterol is significantly reduced, and the risk of cardiovascular disease is reduced; the level of SOD in liver of NAFLD patients can be significantly improved; the inflammation of liver can be significantly improved; the damage of liver tissues of the NAFLD patients can be significantly improved; the expression of an Nrf2 gene in fatty liver cells can be significantly improved; the ability to absorb perfluorooctanoic acid in vitro is strong.

The invention relates to a compound oral preparation, which has protective effect towards the chemical hepatic injury and the preparation method of the compound oral preparation. The compound oral preparation is various kinds of oral preparations comprise the main active components of a kudzuvine root, a Japanese raisin tree seed, a dry ginger, a dried tangerine peel, a rhodiola rosea, an Asiatic pennywort herb, a bupleurum root, a danshen root and an angelica and the officinal auxiliary materials. The invention is provided with reasonable prescription, advanced technology and convenient use and is safe and effective and is fit for being taken for a long time. The function test testifies that the preparation can obviously reduce the contents of serum glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase of an animal module with the hepatic injury caused by CCL₄ and relieve the pathological symptoms of the hepatic injury; the preparation can not only be used as a good auxiliary treatment manner to the patient with the hepatitis but also can be used as health care product for normal people to take for a long time.

The invention discloses a multilayer-film dry chemical reagent strip for measuring glutamic-pyruvic transaminase by using enzyme coupled continuous monitoring assay. The reagent strip comprises four layers of film, namely diffusion film, blood filter film (in two layers) and bottom reaction film and is characterized in that corresponding enzyme reactants are adsorbed to the reaction film, pyruvic acid is generated from L-alanine and sodium Alpha-ketoglutarate under the catalysis of glutamic-pyruvic transaminase, the pyruvic acid acts with reduced coenzyme I(NADH) under the catalysis of lactic dehydrogenase (LDH) to generate NAD+, absorbance at 340 nm is decreased, and the amplitude of decrease is associated with the content of the glutamic-pyruvic transaminase. The reagent strip is applicable to the quick measurement of the activity of glutamic-pyruvic transaminase in human whole blood and serum or plasma, is simple and easy to operate, and is easy to clinically apply and popularize.

The invention discloses a liver protection effect and application of sulforaphen in non-alcoholic fatty liver, and belongs to the fields of biomedicine and food. According to the invention, the sulforaphen can be used for effectively treating liver diseases and decelerating lipid accumulation and steatosis of the liver, has the effect of obviously decelerating non-alcoholic fatty liver, and can reduce the glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase levels in blood, thereby opening a new way to treat fatty liver diseases and liver function impairment, having important meanings for development of edible and medicinal dual-purpose resources, realizing high-value transformation of active plant resources and promoting fine and deep processing and utilization of agricultural products. The sulforaphen having a liver protection effect can be widely used in the fields of food, medicine and the like, and has obvious social benefits and economic benefits.

The present invention relates to medicine technology. The diammonium glycyrrhizinate freeze drying powder for injection includes the following components: diammonium glycyrrhizinate 10-100 wt%, solabilizer 0-90 wt% and excipient 0-80 wt%. Its preparation process includes dissolving the above said components, regulating pH value, filtering, packing and freeze drying. The medicine is used clinically in intravenous dripping for treating chronic organizing hepatitis accompanied with raised glutamic pyruvic transaminase and chronic mobile hepatitis. It has stable quality, long storage period and fast dissolution in water, and may be matched with glucose injection and/or sodium chloride injection clinically.

The invention discloses multifunctional lactobacillus buchneri CCFM1053 for relieving PFOA toxic action as well as fermented food and application thereof. The lactobacillus buchneri CCFM1053 can adsorb PFOA, improve spleen atrophy caused by PFOA exposure, increase content of TNA-alpha in serum after PFOA exposure, increase content of glutamic-pyruvic transaminase, glutamic oxalacetic transaminaseand gamma-glutamyl transpeptidase in serum in mice after PFOA exposure, reduce the content of MDA in liver after PFOA exposure to the normal level, reduce GAH activity, improve intestinal flora disorder, reduce hepatopathy, improve excrement moisture content and first melena discharge time of constipation patients, relieve constipation, improve proliferation of INS-1 cells and expression of MafA genes under the high glucose action and relieve PFOA related diabetes mellitus.

The invention relates to a forage additive for preventing egg-laying hen fatty liver syndrome and application thereof. The forage additive is characterized in that: (1) a safe effective amount of pyrroloquinoline quinone and/or pharmaceutically acceptable salts or esters thereof are/is added into an egg-laying hen forage as the active component; (2) a lucifugal woven bag with a lined (black) plastic membrane is employed for packaging the forage when the forage is stored; and (3) the feeding time is four weeks or more. The application of the forage additive comprises that the forage additive helps fatty-liver egg-laying hens induced by high-energy low-protein daily ration to improve egg laying rate, reduce material-egg ratio, improve egg quality, inhibit vacuolar degeneration and ballooning degeneration of hepatocyte in liver tissue, reduce the content of triglycerides and total cholesterol in blood and reduce the activity of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase. Therefore, pyrroloquinoline quinine has good application prospect for preventing the form and the development of egg-laying hen fatty liver syndrome, and has economic benefit.

The invention relates to the technical field of microorganisms, and discloses complex probiotic and use thereof. The complex probiotic consists of bifidobacterium adolescentis CCFM8630, lactobacillusreuteri CCFM8631, lactobacillus rhamnosus CCFM1044 and lactobacillus casei CCFM711. The effect of relieving metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 used alone or in combination, especially in the reduction of low-density lipoprotein, total cholesterol and liver triglyceride in serum and glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, alkaline phosphatase, IFN-gamma content in the serum and increase the glutathione and superoxide dismutase content in the liver. The decrease or increase range is improved by 7.91%-837.11% compared with the single or double-bacteria combination formula of the CCFM8630 and the CCFM8631. The four-bacteria combination can achieve the remarkable synergistic interaction.

The invention discloses application of L-arabinose in preparing medicines or health-care products for preventing or treating metabolic syndrome, and in particular application of L-arabinose in preparing medicines or health-care products for simultaneously reducing total cholesterol, triglyceride, fasting blood-glucose, blood pressure, waistline and weight, blood uric acid and glutamic-pyruvic transaminase of human body. The applicant discovers that for adults, in a taking dosage range of 10-20g/person/day, total cholesterol, triglyceride, fasting blood-glucose, blood pressure, waistline and weight, blood uric acid and glutamic-pyruvic transaminase of human body can be simultaneously reduced clinically. Not only is functions of the body not damaged, but also digestion and absorption of proteins and vitamins are not affected while the indexes are simultaneously reduced, so that the purpose of improving the functions of the body and preventing and treating metabolic syndrome is realized.

The invention discloses application of schisandrol B in preparation of a medicine for preventing and treating cholestatic liver disease. By giving an excess amount of lithocholic acid, a mice intrahepatic cholestasis model is made, or a mice extrahepatic cholestasis model is made by bile duct ligation, then the mice intrahepatic cholestasis model and the mice extrahepatic cholestasis model are respectively collaboratively given the schisandrol, liver injury can be effectively alleviated, the bile acid level is reduced, glutamic-pyruvic transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) activity are decreased significantly, liver tissue necrosis degree is significantly alleviated, at the same time, total bile acid and total bilirubin content in serum are significantly reduced, and the total bile acid and total bilirubin content discharged with urine are increased. The results show that the schisandrol B can prevent and treat cholestatic liver injury induced by lithocholic acid and bile duct ligation, and prove that the effect mechanism may be involved in regulation of CYP3A11, UGT1A1 and OATP1A4 mediated bile acid metabolism and excretion.

The invention provides an assorted feed for preventing the liver of a tilapia from becoming yellow. The assorted feed has balanced nutrition, and has good growth promotion effect to the tilapia on the basis of meeting normal growth nutrition demands of the tilapia, feed coefficient is reduced, and water deterioration or standard exceeding of water quality cannot be caused easily; meanwhile, serum bilirubin content of the tilapia in a high-temperature feeding period can be reduced effectively, and hepatoenteral circulation of bile is promoted; and activities of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase of serum of the tilapia in the high-temperature feeding period are reduced, and activity of lysozyme of the serum is increased.

The invention relates to new application of borapetoside E for preventing and treating diabetes and hyperlipemia. A research discovers that a compound borapetoside E is capable of obviously reducing the level of blood sugar and blood lipid of HFD (High Fat Diet) induced mice and improving insulin sensitivity of the HFD induced mice. The hypoglycemic and anti-hyperlipidemic effects of 40mg/kg of the compound borapetoside E are superior to those of 200mg/kg of metformin. In addition, the duration time of the hypoglycemic effect is longer than that of 200mg/kg of the metformin, the hypoglycemic effect after drug discontinuance of single drug administration of 40mg/kg of the compound borapetoside E continues for 36 hours, and the duration time after the drug discontinuance of five times of drug administration continues for 4 days. The borapetoside E under the therapeutic dosage has no toxic and side effects, the serum glutamic pyruvic transaminase level is remarkably reduced after successive administration is carried out on the mice for 16 days, serum glutamic oxalacetic transaminase, creatine kinase and creatinine are not obviously changed, and the borapetoside E can be used for preparing drugs, healthcare products and functional food for preventing and treating the diabetes.